Immage Biotherapeutics Corp.
IMMG
Other OTC0.00
USD
- -
- -
Immage Biotherapeutics Corp.
IMMG
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Immage Biotherapeutics Corp. Immage Biotherapeutics Corp. (IMMG) is a biotechnology company focused on developing cancer immunotherapies, including vaccines, oncolytic viruses, adjuvants, and adoptive T-cell technologies targeting melanoma-associated antigen-A (MAGE-A); it employs bioinformatics and outsourced laboratory resources for rapid candidate development, with plans to advance fusion/hybrid antigen vaccines effective against MAGE-A isomers 1-11 that are HLA-free, as well as immunotherapy candidates from its intellectual property library using viral vector constructs for human clinical trials, particularly for breast and prostate cancers. Founded in 2012 by Anton Dormer and Mahesh Narayanan and headquartered at 10411 Motor City Drive, Suite 750, Bethesda, Maryland, the company operates primarily in the United States with a small team of four employees led by CEO Zhi Cong Mou, CTO Anton Dormer, COO Mahesh Narayanan, and CFO Elton Norman. In recent developments, Immage Biotherapeutics initiated a repeat toxicology study for its lead candidate IMT-001 in May 2025, though the board voted to terminate operations as of August 31, 2025, following evaluation of available options, marking a significant wind-down after previously changing its name from Epicure Charcoal, Inc. in June 2015.